Pyc Therapeutics Ltd has released a press release.
Commencement of RP11 Multiple Dose Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
In the deck
Earlier from PYC Therapeutics
- RP11 Drug Candidate Safe and Well Tolerated
- PMS Drug Candidate Effective In Human Brain Cells
- RP11 Clinical Trial Dosing Completed in Cohort 4
- Successful GLP Tox Studies in Second Blinding Eye Disease
- Presentation of RP11 Clinical Trial Data at ARVO Conference
Later from PYC Therapeutics
- Initial Dosing Completed in Cohort 1 of RP11 MAD Study
- Extension of RP11 Single Dose Study Into Multiple Dose Study
- RP11 Clinical Trial Update
- RP11 Clinical Trial Update - Amended
- Visual Improvement in Multiple RP11 Patients
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics